Virgilio, when they went for OS as an endpoint in the melanoma trial, they set themselves up for approval, as most surrogate endpoints are very difficult to get approval on while OS is indisputable. The problem, of course, is that they take so long. Unfortunately, and JUNO's news yesterday confirms this, they were in fact overtaken by the still fast developing and evolving CARt technology. Even though the trial was probably going to meet endpoints, by 2019 there would no longer be the market that appeared to exist at trial design in 2010 for an immunotherapeutic solution. tough luck. Shit happens. As a result of that, the market no longer has great faith (and to a greater or lesser degree, with reason) in the clinical trials proposed and needed by CLBS. On the other hand, CAR-T's will bring a lot of business to PCT. Is PCT now the savior of CLBS... not in my opinion. However, compared to other small development stage bios, it's in a much much stronger position with PCT than betting everything on clinical success like all others, and could very easily be seeing profits of $10-$20 million in three years.
Getting back to the clinical side, unlike yourself, I find real potential value in the deals they've made and trials they've started. Has the market jumped for joy? No, they've lost too much credibility for that to happen. However, with a positive preliminary result in the T1D Sanford 18 cohort mini-trial, things will change dramatically, as they are well positioned, have close FDA cooperation, and should be very able to find a suitor to finish the P-2 and move on. Small market? Sure, but we're still talking, from where we are now, a ten bagger, and we'll get that news, one way or the other, this year.
Anyway, I get that you don't see it that way, and fair enough. that's what makes a market. However, why you'd waste your energy trying to enlighten all the rest of us poor delusional fools lost in the miasma of our dreams I don't get. Oh... that's right. You're not trying to help us at all, but rather butter your shortbread. Well, it's a free country and a big net, so do your damnedest. I'm not a short, but if I was, I'd look for overvalued companies, not undervalued. How do you go down, after all, from the basement?
